ArticleGastroenterology & hepatology2016
A Personalized Approach to Managing Inflammatory Bowel Disease.
Article in Gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Placebo-Controlled Trials in the Management of Crohn's Disease: An Umbrella Review of Meta-Analyses.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature Review.Advances in therapy · 2026Review
- Granzyme B PET Imaging Uncovers Dynamic Patterns of Disease Activity and Therapeutic Response in a Murine Colitis Model.International journal of molecular sciences · 2026Article
- Exploring nurse-patient mutuality in inflammatory bowel disease: a multicenter cross-sectional study.BMC nursing · 2025Article
- Comparative analysis of the pathogenesis in Crohn's disease and ulcerative colitis.World journal of gastroenterology · 2025Article
- Leveraging Organ-on-Chip Models to Investigate Host-Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease.Advanced healthcare materials · 2025Review
- Enhanced Risk of Gastroesophageal Reflux Disease and Esophageal Complications in the Ulcerative Colitis Population.Journal of clinical medicine · 2024Article
- Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects.Journal of clinical medicine · 2024Review
- Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond.SAGE open medicine · 2024Review
- Dealing with Time Estimates in Hospital Cost Accounting: Integrating Fuzzy Logic into Time-Driven Activity-Based Costing.PharmacoEconomics - open · 2023Article
- Contrast Enhanced Ultrasound Molecular Imaging of Spontaneous Chronic Inflammatory Bowel Disease in an Interleukin-2 Receptor αNanomaterials (Basel, Switzerland) · 2022Article
- Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease.Journal of gastroenterology and hepatology · 2021Article
- Endoscopy in inflammatory bowel disease: from guidelines to real life.Therapeutic advances in gastroenterology · 2019Review
- Chronic Model of Inflammatory Bowel Disease in IL-10Theranostics · 2019Article
- US Molecular Imaging of Acute Ileitis: Anti-Inflammatory Treatment Response Monitored with Targeted Microbubbles in a Preclinical Model.Radiology · 2018Article
- Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases.Disease markers · 2018Review
- Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines.American journal of translational research · 2018Article
- Eosinophilic esophagitis: What can we learn from Crohn's disease?United European gastroenterology journal · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of inflammatory bowel disease (IBD) requires a personalized approach to treat what is a heterogeneous group of patients with inherently variable disease courses. In its current state, personalized care of the IBD patient involves identifying patients at high risk for rapid progression to complications, selecting the most appropriate therapy for a given patient, using therapeutic drug monitoring, and achieving the individualized goal that is most appropriate for that patient. The growing body of research in this area allows clinicians to better predict outcomes for individual patients. Some paradigms, especially within the realm of therapeutic drug monitoring, have begun to change as therapy is targeted to individual patient results and goals. Future personalized medical decisions may allow specific therapeutic plans to draw on serologic, genetic, and microbial data for Crohn's disease and ulcerative colitis patients.
Indexed as
Identifiers
27499713PMC4973561What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.